Christodoulidis G, Koumarelas KE, Kouliou MN. Pivotal role of exosomes in diagnosis and treatment of esophageal cancer in a new era of precision medicine. World J Methodol 2024; 14(1): 90624 [PMID: 38577205 DOI: 10.5662/wjm.v14.i1.90624]
Corresponding Author of This Article
Grigorios Christodoulidis, MD, PhD, Surgeon, Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. gregsurg@yahoo.gr
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Grigorios Christodoulidis, Konstantinos Eleftherios Koumarelas, Marina Nektaria Kouliou, Department of General Surgery, University Hospital of Larissa, Larissa 41110, Greece
Author contributions: Christodoulidis G, Konstantinos-Eleftherios K, and Marina-Nektaria K contributed to the preparation of this paper; Christodoulidis G designed the overall concept and outline of the manuscript; Christodoulidis G, Konstantinos-Eleftherios K, and Marina-Nektaria K contributed to the discussion and design of the manuscript; Christodoulidis G, Konstantinos-Eleftherios K, and Marina-Nektaria K contributed to the writing and editing the manuscript, and review of the literature.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Grigorios Christodoulidis, MD, PhD, Surgeon, Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. gregsurg@yahoo.gr
Received: December 8, 2023 Peer-review started: December 8, 2023 First decision: December 21, 2023 Revised: December 23, 2023 Accepted: January 17, 2024 Article in press: January 17, 2024 Published online: March 20, 2024 Processing time: 89 Days and 11.2 Hours
Core Tip
Core Tip: Esophageal cancer (EC) is a global health concern ranking seventh in incidence and sixth in mortality worldwide, with over 604000 new cases and 544000 deaths in 2020. Despite advancements in therapies, nearly half of EC patients experience distant metastasis or therapeutic resistance, resulting in a 5-year survival rate below 25%. Traditional screening methods are limited, necessitating the need for non-invasive alternatives. Liquid biopsy, particularly focusing on exosomes, emerges as a promising option for early EC detection. Exosomes, small vesicles for intercellular communication, carry diverse biomarkers and play a crucial role in tumorigenesis. Notably, exosomal microRNAs, long non-coding RNAs, and circular RNAs show potential as diagnostic and prognostic markers for esophageal squamous cell carcinoma. Beyond diagnosis, exosomes serve as effective delivery tools for therapeutic agents, exhibiting advantages in immunotherapy, gene therapy, and drug delivery, presenting a multifaceted approach in the battle against EC.
